Asia Gout Disease Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
The lockdown in various countries due to COVID 19 pandemic has created an economic burden on the private healthcare sector. Healthcare providers are facing challenges with regards to manpower, equipment, consumables, and other resources to ensure safety in treatment of patients with other diseases, and declining outpatient visits, etc. Moreover, the coronavirus pandemic has negatively impacted the development, production, and supply of drugs and affected growth of the healthcare businesses of various companies across the globe. This has led to closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of products. Thus, COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets.
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/4141
Supply chain and manufacturing activities in India and China have been disrupted due to the global lockdowns, while countries such as Thailand, Indonesia, Singapore, and others are facing problems with regards to transportation of drugs. Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit growth of the Asia gout disease treatment market during the forecast period.
Key players are involved in drug developments, launches, and approvals for the treatment of gout disease, which is projected to drive growth of the Asia gout disease treatment market. For instance, in June 2020, Teijin Pharma Limited conducted clinical research for two test drugs, TMX-049 (for the treatment of Gout, hyperuricemia) and TMX-67HK (Febuxostat) (for the treatment of Gout, hyperuricemia (pediatric patient)). Currently, both the test drugs are in Phase II of the clinical trial.
Similarly, in October 2019, Horizon Therapeutics plc initiated an open-label clinical trial for the evaluation of the use of KRYSTEXXA (pegloticase injection) in adults with chronic gout– also known as uncontrolled gout – who have undergone a kidney transplant to demonstrate that KRYSTEXXA may provide effective disease control without burdening the kidneys.
Moreover, in December 2015, AstraZeneca Plc announced that the U.S. Food and Drug Administration (FDA) approved ZURAMPIC (lesinurad) 200mg tablets in combination with a xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia associated with gout in patients. Post approval, ZURAMPIC (lesinurad) will be available worldwide, including Asia Pacific region.
Key Takeaways of the Asia Gout Disease Treatment Market:
- The Asia gout disease treatment market is expected to exhibit a CAGR of 9.1% during the forecast period (2020-2027), due to the increasing number of drug approvals and launches by key players
- Companies are focused on agreement strategies, in order to strengthen their distribution of drugs across various regions in the Asia gout disease treatment market
- Major players engaged in the Asia gout disease treatment market are AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Hikma Pharmaceuticals Plc., Hikma Pharmaceuticals Plc., Zyla Life Sciences, Horizon Therapeutics plc, JW Pharmaceutical CORPORATION, and LG Chem
Request Here PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/4141
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Asia Gout Disease Treatment Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Asia Gout Disease Treatment Industry Impact
Chapter 2 Asia Gout Disease Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Asia Gout Disease Treatment (Volume and Value) by Type
2.3 Asia Gout Disease Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Asia Gout Disease Treatment Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 Company Profiles and Key Figures in Asia Gout Disease Treatment Business
Chapter 6 Asia Gout Disease Treatment Market Forecast (2022-2028)
Chapter 7 Conclusions
Direct Buy This Premium Research Report, Click Here @ https://www.coherentmarketinsights.com/insight/buy-now/4141
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027